Brii Biosciences Limited (02137.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 0.88

From 52W high−61.69%

Volume326000.00

Market capHKD 638.86M

P/E (TTM)—

P/S (TTM)29.9x

Div yield—

Key dataSep 18, 2026

Open

HKD 0.88

From 52W high

−61.69%

Volume

326000.00

Market cap

HKD 638.86M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.8x

P/E (TTM)

—

RSI (14)

41.0

MomentumView details →

1D Return

+0.57%

YTD Return

−37.23%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

4.8x

EV/Sales

−69.5x

P/S (TTM)

29.9x

P/B (TTM)

0.2x

ProfitabilityView details →

Gross Margin

63.08%

Net Margin

−918.14%

EBITDA Margin

−1433.03%

ROE (TTM)

−7.58%

ROA (TTM)

−7.64%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−44.77%

EPS YoY

+53.18%

FCF YoY

+70.32%

Revenue CAGR 3Y

−29.46%

EPS CAGR 3Y

+57.14%

EBITDA YoY

+25.60%

MomentumView details →

1D Return

+0.57%

YTD Return

−37.23%

1Y Return

−57.04%

RSI (14)

41.0

vs 50D SMA

−7.47%

vs 200D SMA

−30.61%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

52.24x

Quick Ratio

52.24x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.16

EPS Surprise

−47.00%

Beats (12Q)

0/12

Next Q EPS Est

—

Avg Surprise (4Q)

−47.00%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

51.42M

Net Income (TTM)

−543.66M

Op. CF (TTM)

−589.32M

Next earningsMar 19, 2027 →

Latest newsMore news →

Brii Biosciences reported its interim results for the six months ended June 2026, with a narrowed net loss attributable to shareholders of RMB 101 million, compared to a loss of RMB 148 million in the same period last year, and no interim dividend declared.31d ago

Similar companies

Wuhan YZY Biopharma Co Ltd02496.HK Neurogene Inc.NGNE Altimmune, Inc.ALT Monopar Therapeutics Inc.MNPR OmniAb, Inc.OABI Crescent Biopharma, Inc.CBIO Find similar companies →

Latest newsMore news →

Brii Biosciences reported its interim results for the six months ended June 2026, with a narrowed net loss attributable to shareholders of RMB 101 million, compared to a loss of RMB 148 million in the same period last year, and no interim dividend declared.31d ago